Beijing Sun-Novo Pharmaceutical Research Co.Ltd(688621) independent directors
Special instructions and independent opinions on the company’s external guarantee
In accordance with the guidelines for the supervision of listed companies No. 8 – regulatory requirements for capital transactions and external guarantees of listed companies and the relevant provisions of the Listing Rules of Shanghai Stock Exchange on the science and innovation board, as an independent director of Beijing Sun-Novo Pharmaceutical Research Co.Ltd(688621) (hereinafter referred to as the “company”), we have verified the external guarantees of the company in 2021 based on the principles of impartiality, fairness and objectivity, Special notes and independent opinions are hereby issued as follows:
1、 During the reporting period, the company strictly complied with relevant laws and regulations and relevant provisions of the CSRC, and did not provide illegal guarantees for controlling shareholders and other related parties.
2、 In 2021, the company’s external guarantees were all guarantees provided by the company to its wholly-owned subsidiaries, including the guarantee provided by the company for the wholly-owned subsidiaries Beijing novo Demi Pharmaceutical Technology Co., Ltd. and Beijing Sunshine Demi Pharmaceutical Technology Co., Ltd. to apply for comprehensive credit from the bank. The guarantee amount of the actual loan during the reporting period was 15 million yuan.
3、 During the reporting period, the company’s external guarantees strictly complied with relevant laws, regulations, the articles of association and other relevant provisions, and there was no violation of the relevant provisions of the CSRC and Shanghai Stock Exchange.
(no text below)
(there is no text on this page, only the signature page of Beijing Sun-Novo Pharmaceutical Research Co.Ltd(688621) independent director’s special instructions and independent opinions on the company’s external guarantee) independent director: Hu Xuefeng (signature):
February 25, 2022 (there is no text on this page, only the signature page of Beijing Sun-Novo Pharmaceutical Research Co.Ltd(688621) independent director’s special instructions and independent opinions on the company’s external guarantee) independent director: Shu Zhemin (signature):
February 25, 2022 (there is no text on this page, only the signature page of Beijing Sun-Novo Pharmaceutical Research Co.Ltd(688621) independent director’s special instructions and independent opinions on the company’s external guarantee) independent director: he zhuangkun (signature):
February 25, 2022
